Company profilePharmaceutical#1011 of 1,318 in Pakistan✓ No DRAP alerts

Wyeth Pakistan Limited DSL: 371

Pharmaceutical company · 3 brands · 6 molecules

Ranked #8 of 14 companies in Oestrogens

3 registered products 6 pharmaceutical brands 6 distinct molecules 0 DRAP alerts

Company overview

3
registered products
6
pharmaceutical brands
6
distinct molecules
3
therapeutic classes
0
DRAP alerts

Wyeth Pakistan Limited DSL: 371 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 3 product registrations across 6 distinct molecules. Its portfolio is concentrated in Oestrogens and Hormone Regulators. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Wyeth

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

1
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20261

Top molecules by brand count

Conjugatedestrogensusp ........0.3Mg (Bulkim1 brand
Pneumococcal Polysaccharide Serotype 1 ...... 2.2 Μg (Conjugated To C1 brand
Pneumococcal Polysaccharide Serotype 1 ...... 2.2 Μg Ug1 brand

Therapeutic classes

Oestrogens · 1Hormone Regulators · 1Vaccines · 1

Conditions treated

Hormonal Therapy · 1Pneumonia · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official3 products · Rs 1,105.75 – Rs 1,354,005.54
DVAGO1 products · Rs 9,180.4 – Rs 9,180.4
Servaid2 products · Rs 616.5 – Rs 6,855.78
Median across source: Rs 9,180.4

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SHAIGAN PHARMACEUTICALS (PVT) LTD. holds 139 molecules not in this portfolio
AlbendazoleAmikacinAmlodipineAmlodipine BasylateArtemetherAscorbic Acid
ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 156 molecules not in this portfolio
AlbuterolAmikacinAminophyllineAmlodipineAmlodipine BaseAmmonium Chloride

Get the full profile for Wyeth

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.